Eli Lilly and Company (LLY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Eli Lilly and Company (LLY) has a cash flow conversion efficiency ratio of 0.370x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($8.84 Billion) by net assets ($23.85 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Eli Lilly and Company - Cash Flow Conversion Efficiency Trend (1989–2024)
This chart illustrates how Eli Lilly and Company's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Eli Lilly and Company for a breakdown of total debt and financial obligations.
Eli Lilly and Company Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eli Lilly and Company ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Samsung Electronics Co Ltd
KO:005930
|
0.055x |
|
Walmart Inc. Common Stock
NYSE:WMT
|
0.095x |
|
Walmart Inc. Common Stock
NASDAQ:WMT
|
0.133x |
|
Walmart Inc
SA:WALM34
|
0.286x |
|
Eli Lilly and Company
SA:LILY34
|
0.122x |
|
JPMorgan Chase & Co
NYSE:JPM
|
1.016x |
|
Berkshire Hathaway Inc
NYSE:BRK-B
|
0.020x |
|
Exxon Mobil Corp
NYSE:XOM
|
0.048x |
Annual Cash Flow Conversion Efficiency for Eli Lilly and Company (1989–2024)
The table below shows the annual cash flow conversion efficiency of Eli Lilly and Company from 1989 to 2024. For the full company profile with market capitalisation and key ratios, see Eli Lilly and Company (LLY) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $14.27 Billion | $8.82 Billion | 0.618x | +58.30% |
| 2023-12-31 | $10.86 Billion | $4.24 Billion | 0.390x | -40.64% |
| 2022-12-31 | $10.78 Billion | $7.08 Billion | 0.657x | -17.10% |
| 2021-12-31 | $9.15 Billion | $7.26 Billion | 0.793x | -28.92% |
| 2020-12-31 | $5.83 Billion | $6.50 Billion | 1.116x | -37.73% |
| 2019-12-31 | $2.70 Billion | $4.84 Billion | 1.792x | +253.85% |
| 2018-12-31 | $10.91 Billion | $5.52 Billion | 0.506x | +5.22% |
| 2017-12-31 | $11.67 Billion | $5.62 Billion | 0.481x | +39.70% |
| 2016-12-31 | $14.08 Billion | $4.85 Billion | 0.345x | +69.56% |
| 2015-12-31 | $14.59 Billion | $2.96 Billion | 0.203x | -29.87% |
| 2014-12-31 | $15.39 Billion | $4.46 Billion | 0.290x | -10.88% |
| 2013-12-31 | $17.64 Billion | $5.74 Billion | 0.325x | -9.46% |
| 2012-12-31 | $14.77 Billion | $5.30 Billion | 0.359x | -32.82% |
| 2011-12-31 | $13.54 Billion | $7.23 Billion | 0.534x | -3.24% |
| 2010-12-31 | $12.41 Billion | $6.86 Billion | 0.552x | +21.36% |
| 2009-12-31 | $9.53 Billion | $4.34 Billion | 0.455x | -57.98% |
| 2008-12-31 | $6.74 Billion | $7.30 Billion | 1.083x | +181.95% |
| 2007-12-31 | $13.42 Billion | $5.15 Billion | 0.384x | +6.10% |
| 2006-12-31 | $10.98 Billion | $3.98 Billion | 0.362x | +104.20% |
| 2005-12-31 | $10.79 Billion | $1.91 Billion | 0.177x | -32.52% |
| 2004-12-31 | $10.92 Billion | $2.87 Billion | 0.263x | -29.64% |
| 2003-12-31 | $9.76 Billion | $3.65 Billion | 0.373x | +49.22% |
| 2002-12-31 | $8.27 Billion | $2.07 Billion | 0.250x | -51.44% |
| 2001-12-31 | $7.10 Billion | $3.66 Billion | 0.515x | -16.47% |
| 2000-12-31 | $6.05 Billion | $3.73 Billion | 0.617x | +18.09% |
| 1999-12-31 | $5.01 Billion | $2.62 Billion | 0.523x | -11.98% |
| 1998-12-31 | $4.43 Billion | $2.63 Billion | 0.594x | +18.86% |
| 1997-12-31 | $4.81 Billion | $2.40 Billion | 0.500x | +53.01% |
| 1996-12-31 | $6.10 Billion | $1.99 Billion | 0.326x | -2.80% |
| 1995-12-31 | $5.43 Billion | $1.82 Billion | 0.336x | +17.39% |
| 1994-12-31 | $5.36 Billion | $1.53 Billion | 0.286x | -13.83% |
| 1993-12-31 | $4.57 Billion | $1.52 Billion | 0.332x | +9.49% |
| 1992-12-31 | $4.89 Billion | $1.48 Billion | 0.303x | +20.03% |
| 1991-12-31 | $4.97 Billion | $1.25 Billion | 0.253x | -40.59% |
| 1990-12-31 | $3.47 Billion | $1.47 Billion | 0.425x | +54.71% |
| 1989-12-31 | $3.76 Billion | $1.03 Billion | 0.275x | -- |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardi… Read more